Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AbCellera and Eli Lilly partner to tackle the coronavirus

AbCellera and Eli Lilly partner to tackle the coronavirus

16th March 2020

AbCellera and Eli Lilly (EL) have entered into a co-development agreement to develop antibody therapies in aid to fight against the coronavirus. The partnership will leverage EL’s global capabilities and AbCellera’s pandemic response platform for the therapeutic antibodies fast development, manufacturing and distribution.

In a blood sample from a recovered COVID-19 patient in the U.S., AbCellera screened over 5 million immune cells to determine which ones developed antibodies that allowed recovery from the illness. From this, Abcellera identified five-hundred fully human antibody sequences, and now they will screen the antibodies to identify which ones are most effective against coronavirus. From this, Abcellera identified five-hundred fully human antibody sequences, and will now scan the antibodies to determine which ones are most effective against the coronavirus.

AbCellera’s CEO, Carl Hansen, stated: “AbCellera’s platform has delivered, with unprecedented speed, by far the world’s largest panel of anti-SAR-CoV-2 antibodies. In eleven days we’ve discovered hundreds of antibodies against the SARS-CoV-2 virus responsible for the current outbreak, moved into functional testing with global experts in virology and signed a co-development agreement with one of the world’s leading biopharmaceutical companies.”

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.